Literature DB >> 28838387

TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1α.

Christoph Wohlkoenig1, Katharina Leithner2, Andrea Olschewski3, Horst Olschewski4, Andelko Hrzenjak5.   

Abstract

OBJECTIVES: Lung cancer is the leading cause of cancer death worldwide. Like in all solid tumors, hypoxia is common in lung cancer and contributes to apoptosis, and thus chemotherapy resistance. However, the underlying mechanisms are not entirely clear. TR3 (NR4A1, Nur77) is an orphan nuclear receptor that induces apoptosis and may mediate chemotherapy-induced apoptosis in cancer cells.
MATERIALS AND METHODS: We used A549, H23 and H1299 cell lines to investigate how TR3-mediated apoptosis is affected by hypoxia in non-small cell lung cancer (NSCLC) cells. Cell culture, western blot analysis, apoptosis assay, and siRNA-mediated gene silencing were performed in this study. RESULTS AND
CONCLUSION: The TR3 activator cytosporone B was used to investigate TR3-mediated apoptosis in NSCLC cells under normoxic and hypoxic conditions. Cytosporone B induced apoptosis in a concentration-dependent manner. Chronic moderate hypoxia induced a significant down-regulation of TR3. Accordingly, the cytosporone B effect was reduced under these conditions. Hypoxia-induced down-regulation of TR3 was mediated by hypoxia-inducible factor 1α. Our immunoblotting analysis and expression data from a public dataset suggest that TR3 is downregulated in NSCLC. In conclusion, our findings suggest that hypoxia-induced down-regulation of TR3 might play an important role for hypoxia-induced apoptosis resistance in NSCLC.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cytosporone B; HIF-1α; Hypoxia; Non-small cell lung cancer; TR3

Mesh:

Substances:

Year:  2017        PMID: 28838387     DOI: 10.1016/j.lungcan.2017.06.013

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  6 in total

1.  Knockdown of lncRNA HIF1A-AS2 increases drug sensitivity of SCLC cells in association with autophagy.

Authors:  Ebru Güçlü; Canan Eroğlu Güneş; Ercan Kurar; Hasibe Vural
Journal:  Med Oncol       Date:  2021-08-11       Impact factor: 3.064

Review 2.  Characteristics of Nur77 and its ligands as potential anticancer compounds (Review).

Authors:  Lingjuan Wu; Liqun Chen
Journal:  Mol Med Rep       Date:  2018-09-27       Impact factor: 2.952

3.  DNA Methylation Changes in Regional Lung Macrophages Are Associated with Metabolic Differences.

Authors:  David A Armstrong; Youdinghuan Chen; John A Dessaint; Daniel S Aridgides; Jacqueline Y Channon; Diane L Mellinger; Brock C Christensen; Alix Ashare
Journal:  Immunohorizons       Date:  2019-07-02

4.  Hypoxia upregulates the expression of lncRNA H19 in non-small cell lung cancer cells and induces drug resistance.

Authors:  Haiyan Li; Jinwei Wang; Yingying Jin; Jian Lin; Liuyang Gong; Youzu Xu
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

Review 5.  Therapeutic potential of NR4A1 in cancer: Focus on metabolism.

Authors:  Shan Deng; Bo Chen; Jiege Huo; Xin Liu
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

Review 6.  The Paradoxical Roles of Orphan Nuclear Receptor 4A (NR4A) in Cancer.

Authors:  Stephen Safe; Keshav Karki
Journal:  Mol Cancer Res       Date:  2020-10-26       Impact factor: 6.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.